Close Menu

NEW YORK -- Fulgent Genetics plans to offer up to $75 million of its securities, it said in a document filed with the US Securities and Exchange Commission on Monday. 

The Temple City, California-based firm has not priced its offering yet but said that it plans to offer from time to time units of its common stock, preferred stock, one or more debt securities, warrants, or rights to such securities in one or more series. 

Fulgent offers testing to clinical and research customers for hereditary genetic conditions. 

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

Bioethicists disagree with a research team's decision to allow the return of risk results for adult-onset conditions from a newborn sequencing project, according to Reuters.

Alterations to particular gene may enable the Quechua of Peru to better tolerate high-altitude life, Ars Technica reports.

Nature News reports that additional South Korean researchers have included the names of children on scientific papers when they did not contribute to the work.

In PLOS this week: statistical approach to prioritize rare variant searches, gene expression alterations in chronic obstructive pulmonary disease, and more.